First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Medically reviewed by Doru Paul, MD Treatment for renal cell carcinoma can vary depending on the size of your tumor, your ...

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

Renal Cell Carcinoma Highlights From ASCO GU 2024 Key data in renal cell carcinoma from ASCO GU 2024 includes pembrolizumab in early higher-risk RCC, belzutifan in advanced disease, and ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

In draft guidance, the agency has said that while Keytruda (pembrolizumab) added to chemotherapy is more effective than chemo alone. Its long-term benefits are uncertain. Moreover, NICE says there ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.

The first overall survival analysis of the KEYNOTE-522 trial demonstrated that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall ...